SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Raymond James Maintains Outperform on Amedisys, Lowers Price Target to $210

Raymond James maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $225 to $210.

Benzinga · 05/11/2020 11:16

Raymond James maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $225 to $210.